Cyclacel Pharmaceuticals, Inc.
CYCC
$0.23
-$0.0152-6.20%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Net Income | 67.56% | 40.22% | 49.24% | 28.95% | -18.37% |
| Total Depreciation and Amortization | -85.71% | -75.00% | -75.00% | 0.00% | 0.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -72.87% | -49.86% | -50.13% | -22.61% | -10.05% |
| Change in Net Operating Assets | -175.20% | -100.05% | 257.92% | -43.33% | 170.22% |
| Cash from Operations | 24.01% | -136.32% | 92.96% | 24.36% | 42.08% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | 1,040.22% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | 0.00% | 0.00% |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 98.00% | 12,431.37% | -58.00% | 2,278.57% | -103.26% |
| Foreign Exchange rate Adjustments | 137.31% | -103.53% | -357.14% | 247.44% | -306.15% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 28.48% | 351.93% | 91.61% | 52.14% | 21.43% |
